ATROPINE SULFATE injection, solution

Ülke: ABD

Dil: İngilizce

Kaynak: NLM (National Library of Medicine)

Aktif bileşen:

ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I)

Mevcut itibaren:

Fresenius Kabi USA, LLC

INN (International Adı):

ATROPINE SULFATE

Kompozisyon:

ATROPINE SULFATE 0.4 mg in 1 mL

Uygulama yolu:

INTRAVENOUS

Reçete türü:

PRESCRIPTION DRUG

Terapötik endikasyonlar:

Atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. None. Risk Summary Limited available data with Atropine Sulfate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes (see Data).  There are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see Clinical Considerations).   Animal reproduction studies have not been conducted with Atropine Sulfate Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies

Ürün özeti:

Atropine Sulfate Injection, USP is a non-pyrogenic, isotonic, clear solution and is supplied as follows: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. After initial use, store between 20° to 25°C (68° to 77°F) and discard within 24 hours. www.fresenius-kabi.com/us 451539 Issued: March 2018  

Yetkilendirme durumu:

New Drug Application

Ürün özellikleri

ATROPINE SULFATE - ATROPINE SULFATE INJECTION, SOLUTION
FRESENIUS KABI USA, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ATROPINE SULFATE INJECTION SAFELY
AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ATROPINE SULFATE
INJECTION. ATROPINE SULFATE
INJECTION, FOR INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS
OR ENDOTRACHEAL USE.
INITIAL U.S. APPROVAL: 1960
INDICATIONS AND USAGE
Atropine is a muscarinic antagonist indicated for temporary blockade
of severe or life threatening muscarinic effects. (1)
DOSAGE AND ADMINISTRATION
• Dosage is individualized by use, refer to the full prescribing
information for recommended adult and pediatric dosages
(2.2, 2.3).
• Patients with Ischemic Heart Disease: Do not exceed 0.04 mg/kg.
(2.4, 5.2)
DOSAGE FORMS AND STRENGTHS
Injection: 8 mg per 20 mL (0.4 mg per mL) multiple dose glass vial (3)
CONTRAINDICATIONS
None. (4)
WARNINGS AND PRECAUTIONS
Hypersensitivity (5.1)
Worsening of Ischemic Heart Disease (5.2)
Acute Glaucoma (5.3)
Pyloric obstruction (5.4)
Complete urinary retention (5.5)
Viscid plugs (5.6)
ADVERSE REACTIONS
Most adverse reactions are directly related to atropine’s
antimuscarinic action. Dryness of the mouth, blurred vision,
photophobia and tachycardia commonly occur with chronic administration
of therapeutic doses. (6)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT FRESENIUS KABI USA, LLC
AT 1-800-551-7176 OR FDA AT
1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
_Mexiletine_: Decreases rate of mexiletine absorption. (7.1)
REVISED: 1/2018
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 General Administration
2.2 Adult Dosage
2.3 Pediatric Dosage
2.4 Dosing in Patients with Ischemic Heart Disease
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity
5.2 Worsening of Ischemic Heart Disease
5.3 Acute Glaucoma
5.4 Pyloric Obstruction
5.5 Complete Urinary Retention
5.6 Viscid P